Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

NCT04281498 is registered in ClinicalTrials.gov with John Mascarenhas as lead sponsor.

NCT NCT04281498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04281498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Lead sponsor
John Mascarenhas
Phase
Phase 2
Overall status
Completed
Start date
January 14, 2021
Completion date
May 30, 2023
Enrollment
6 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated/blast-phase myeloproliferative neoplasm, chronic-phase myelofibrosis, idh2 mutation